Abstract:Background and objective: The major causes of mortality among patients who survive acute lung injury/ARDS (ALI/ARDS) are due to the extensive tissue remodelling and fibrosis. Use of high-dose glucocorticoids to reduce these inflammatory and fibroproliferative responses has been shown to do more harm than good. Recently, Meduri et al. found that the early use of low-dose prolonged methylprednisolone in patients with severe ALI/ARDS significantly relieved the systemic inflammatory response and improved pulmonary and extrapulmonary organ function. This study investigated the therapeutic effect of low-dose dexamethasone (Dex) on inflammation and fibrosis in LPS-induced ALI in rats and its influence on the expression of the pulmonary glucocorticoid receptor (GR).Methods: Eighty Wistar rats were randomly divided into four groups: a control group (intraperitoneal normal saline injection (5 mL/kg) throughout experiment, n = 24); the LPS model group (LPS injection (5 mg/kg) for 3 days and normal saline thereafter, n = 24); the LPS + Dex group (LPS injection for 3 days and Dex solution (5 mg/kg) thereafter, n = 16); and the Dex group (normal saline injection (5 mL/kg) for 3 days and Dex solution (5 mg/kg) thereafter, n = 16). Levels of tumor necrosis factor-alpha, matrix metallopeptidase-9 and procollagen N-terminal propeptide type I in BAL fluid were examined by ELISA on the third, seventh and fourteenth days after injection. Pulmonary hydroxyproline content was measured and histological examination was performed with haematoxylin-eosin and Victoria blue-ponceau. Pulmonary distribution of GR-positive cells was examined immunohistochemically, and expression of GR mRNA and protein was determined by RT-PCR and western blot analysis.Results: Histological assessments showed that pulmonary fibrosis occurred in parallel with inflammation in the rat ALI model. Compared with the LPS group, the inflammation and fibrosis parameters were significantly improved in the LPS + Dex group at different periods after injection (P < 0.05 or P < 0.01), although parameters in the LPS + Dex group were not as good as those of the control group. GR mRNA and protein expression in the LPS + Dex group were markedly higher than that of the LPS group on the seventh and the fourteenth days (both P < 0.01). Western blotting showed that Dex also promoted the nuclear translocation of GR protein.Conclusion: Low-dose Dex can reduce pulmonary inflammation and fibrosis after LPS-induced ALI in rats and can elevate GR expression in the lung, probably through upregulating GR levels and promoting the nuclear translocation of GR protein.

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Regulation of Microrna-223-3p and HDAC4

The Protective Effect of Dexmedetomidine on LPS-induced Acute Lung Injury Through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR Pathways

Dexmedetomidine Ameliorates LPS Induced Acute Lung Injury Via GSK-3β/STAT3-NF-κB Signaling Pathway in Rats

The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways.

Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats.

Effect of Dexmedetomidine on JAK2/STAT3 Signaling Pathway in Mice with Endotoxin-Induced Acute Lung Injury

Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in Vivo and in Vitro

Dihydrotanshinone Attenuates LPS-Induced Acute Lung Injury in Mice by Upregulating LXRα.

Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway

Dexmedetomidine Alleviates Blunt Chest Trauma and Hemorrhagic Shock‑resuscitation‑induced Acute Lung Injury Through Inhibiting the NLRP3 Inflammasome.

Effects of Dexmedetomidine on NLRP3 Inflammasome During Acute Lung Injury Induced by Blunt Chest Trauma and Hemorrhagic Shock-Resuscitation in Rats

Effects of dexmedetomidine on the expression profile of tsRNAs in LPS‐induced acute lung injury

Danshensu methyl ester attenuated LPS-induced acute lung injury by inhibiting TLR4/NF-κB pathway

Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway

Low-Dose Dexamethasone Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Rats and Upregulates Pulmonary Glucocorticoid Receptors

Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting the NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway.

Dexmedetomidine Alleviates Lipopolysaccharide-Induced Hippocampal Neuronal Apoptosis Via Inhibiting the P38 MAPK/c-Myc/CLIC4 Signaling Pathway in Rats

Dose-response and Mechanism of Protective Functions of Selective Alpha-2 Agonist Dexmedetomidine on Acute Lung Injury in Rats.

Role of Nuclear Factor-Kappa B Activation in Mice with Acute Lung Injury Induced by Lipopolysaccharide

Effect of Dexmedetomidine on Mitochondrial Dynamics in Mice with Endotoxin-Induced Acute Lung Injury

Tetramethylpyrazine ameliorates LPS-induced acute lung injury via the miR-369-3p/DSTN axis